RedHill Biopharma has sold its 70% stake in Talicia to Apotex Health Corp. for an upfront payment of $18 million and up to $35 million in potential sales milestones. This deal strengthens RedHill's liquidity and funds its commercial expansion plans, focusing on larger product opportunities and operational profitability. Apotex, having acquired the remaining 30% stake via Cumberland Pharmaceuticals, will now fully own Talicia, a treatment targeting H. pylori infection. RedHill aims to scale its gastrointestinal franchise with new FDA-approved products following this transaction.
An arbitrator ruled in August 2025 that Gemini did not mislead users or neglect due diligence in its Earn lending program, which collapsed after its partner Genesis Global Capital faced a liquidity crisis. The claim was filed by an Earn user in late ...
The Franklin FTSE South Korea ETF (FLKR), a top international ETF performer especially after its 2026 breakout, has seen its previous valuation discount to emerging markets close. This removes a key bullish factor for the ETF. South Korea's equity ma...
Eli Lilly's Phase 3b trials show that combining Taltz (ixekizumab) and Zepbound (tirzepatide) maintains or improves psoriasis and psoriatic arthritis outcomes at 52 weeks compared to Taltz alone in patients with obesity. The combo also sustains benef...
Bitcoin briefly surpassed $81,000 before falling back to around $78,545 on August 31, facing resistance near the $80,000 mark. This pullback coincides with weakening signals from spot ETF demand, rising Bitcoin reserves on Binance to a 2026 high of a...
The XRP Ledger is considering two key amendments, XLS-65 and XLS-66, which would introduce Single Asset Vaults and lending protocols to enable on-chain institutional credit. Currently, support from validators is around 34-37%, far below the 80% neede...
